These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27583770)

  • 1. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
    Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
    De Lucca GV; Shi Q; Liu Q; Batt DG; Beaudoin Bertrand M; Rampulla R; Mathur A; Discenza L; D'Arienzo C; Dai J; Obermeier M; Vickery R; Zhang Y; Yang Z; Marathe P; Tebben AJ; Muckelbauer JK; Chang CJ; Zhang H; Gillooly K; Taylor T; Pattoli MA; Skala S; Kukral DW; McIntyre KW; Salter-Cid L; Fura A; Burke JR; Barrish JC; Carter PH; Tino JA
    J Med Chem; 2016 Sep; 59(17):7915-35. PubMed ID: 27531604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
    Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
    Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
    J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR.
    Li R; Du Y; Gao Z; Shen J
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
    Yip SH; Wu DR; Li P; Sun D; Watterson SH; Zhao R; Tino J; Mathur A
    J Chromatogr A; 2019 Feb; 1586():106-115. PubMed ID: 30578026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
    Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
    Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.
    Srivastava AS; Ko S; Watterson SH; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Yip S; Li P; Sun D; Wu DR; Dai J; Wang C; Zhang Y; Wang B; Pawluczyk J; Kempson J; Zhao R; Hou X; Rampulla R; Mathur A; Galella MA; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
    ACS Med Chem Lett; 2020 Nov; 11(11):2195-2203. PubMed ID: 33214829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
    Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
    Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
    Gillooly KM; Pulicicchio C; Pattoli MA; Cheng L; Skala S; Heimrich EM; McIntyre KW; Taylor TL; Kukral DW; Dudhgaonkar S; Nagar J; Banas D; Watterson SH; Tino JA; Fura A; Burke JR
    PLoS One; 2017; 12(7):e0181782. PubMed ID: 28742141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
    Marcotte DJ; Liu YT; Arduini RM; Hession CA; Miatkowski K; Wildes CP; Cullen PF; Hong V; Hopkins BT; Mertsching E; Jenkins TJ; Romanowski MJ; Baker DP; Silvian LF
    Protein Sci; 2010 Mar; 19(3):429-39. PubMed ID: 20052711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
    Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Gallion S; Hymowitz SG; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Maurer B; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Sowell CG; Wang X; Wong H; Xiong JM; Xu J; Zhao Z; Currie KS
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1333-7. PubMed ID: 25701252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.